Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Phase: Phase 2
Diagnosis: Pediatric Brain Tumor
NCT ID: NCT01288235
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 10-206
Some patients with brain tumors receive standard radiation to help prevent tumor growth. Although standard radiation kills tumor cells, it can also damage normal tissue in the process and lead to more side effects. This research study is looking at a different form of radiation called proton radiotherapy which helps spare normal tissues while delivering radiation to the tumor or tumor bed. Proton techniques irradiate 2-3 times less normal tissue then standard radiation. This therapy has been used in treatment of other cancers and information from those other research studies suggests that this therapy may help better target brain tumors then standard radiation.
Dana-Farber Cancer Institute, Massachusetts General Hospital
Karen Marcus, MD,
Brigham and Women's Hospital
Torunn Yock, MD,
Massachusetts General Hospital
Dana-Farber Cancer Institute:
Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP,
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
- Biopsy proven low grade glioma or astrocytoma, ependymoma, craniopharyngioma,
meningioma, neurocytoma, medulloblastoma or gangliogliomas or other rare tumor
requiring tumor bed or tumor irradiation. Patients with a presumed diagnosis of
optic glioma or gliomas based on imaging and clinical characteristics will also be
allowed on this trial.
- Patients with biopsy proven high grade glioma (excluding GBM) and a gross total
resection and patients with non-disseminated atypical teratoid rhabdoid (ATRT) may
also be included.
- Pathologic diagnosis must be based on pathology or pathology review by Department of
Pathology at MGH or another DF/HCC institution.
- Age between 1-25 years.
- Life expectancy of greater than 1 year.
- ECOG Performance Status 0, 1, 2 or 3 or Lansky performance status 30 or greater.
- Girls and women of child-bearing potential and men must agree to use adequate
contraception prior to study entry and for the duration of study participation.
- Participants who have had radiotherapy to the site to be treated.
- Participants with known spinal or distant metastases. Patients with ependymoma,
medulloblastoma or germinoma must have metastatic workup including spine MRI to rule
- Uncontrolled intercurrent illness that would limit compliance with study
- Pregnant or breastfeeding women.
- Patients who cannot participate in contributing to the neurocognitive outcomes due to
severe neurologic impairment or language barrier (ie not English or Spanish speaking)
will be excluded from this study.